X4 Pharmaceuticals Partners With Norgine to Commercialize Immunotherapy in Europe, Other Regions

MT NewswiresJan 13 23:08

Express News | X4 Pharmaceuticals Inc - to Submit Maa to EMA for Mavorixafor in Whim Syndrome

BreakingsJan 13 20:35

Express News | X4 Pharmaceuticals Inc - to Receive €28.5 Mln Upfront, up to €226 Mln in Milestones

BreakingsJan 13 20:35

X4 Pharmaceuticals and Norgine Enter Into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

GlobeNewswireJan 13 20:35

X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) High Institutional Ownership Speaks for Itself as Stock Continues to Impress, up 99% Over Last Week

Simply Wall StDec 12, 2024 19:26

X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & Exposition

X4 PharmicalsDec 4, 2024 13:00